Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A head-to-head clinical phase 1b trial of the APG777 in combination with APG990 (APG279 program) against Dupixent in moderate-to-severe AD of APG279

Next Previous
X
Search
Trial Profile

A head-to-head clinical phase 1b trial of the APG777 in combination with APG990 (APG279 program) against Dupixent in moderate-to-severe AD of APG279

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG 777 (Primary) ; APG 990 (Primary) ; Dupilumab
  • Indications Atopic dermatitis
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Mar 2025 company is looking for , planned coformulation combination of APG777 and APG990 approach, which company named APG279, if there will be separate FDC RDI available in future , pls change RDI accordingly
    • 03 Mar 2025 According to an Apogee Therapeutics media release, data expected in the second half of 2026.
    • 28 Feb 2025 trial event According to an Apogee Therapeutics media release, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for its combination approach for APG777 + APG990.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top